The Study
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
This study is like taking apart a broken lock and showing how a new key fits inside it and stops it from turning. It doesn't prove the key will work on real doors in real houses—it just shows it works on one lock in a lab.
Analysis score
Maximum 0 for a computational/algorithm study.
Where the score came from
Scientists found a hidden spot on a broken cancer protein (K-Ras G12C) and built a key that only fits that spot. When the key locks in, it tricks the protein into staying 'off' and stops it from telling cells to grow.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means the drug can selectively kill cancer cells with this specific mutation while sparing healthy cells, which is a major breakthrough for targeted cancer therapy.
- 2The drug binds only to the mutant protein (not normal ones), shifts the protein’s favorite molecule from GTP to GDP (3.5x more), and blocks its connection to Raf (a growth signal).
- 3In cells, it killed cancer cells with this mutation at 0.32 μM.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Nature
Year
2013
Authors
J. Ostrem, U. Peters, M. Sos, J. Wells, K. Shokat
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.